thiophenes has been researched along with 4-(((r)-1-(benzo(b)thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl)-(3-chloro-benzyl)-amino)-butyric acid in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Babel, M; Beaumont, S; Bienvenu, N; Blanqué, R; Brys, R; Cherel, L; Christophe, T; Crescenzi, B; De Lemos, E; De Vos, S; Delerive, P; Deprez, P; Djata, F; Dupont, S; Fletcher, S; Kopiejewski, S; L'Ebraly, C; Lavazais, S; Lefrançois, JM; Manioc, M; Nelles, L; Oste, L; Pizzonero, M; Polancec, D; Quénéhen, V; Saniere, L; Soulas, F; Triballeau, N; van der Aar, EM; Vandeghinste, N; Wakselman, E | 1 |
| Hansen, AH; Hudson, BD; MacKenzie, AE; Milligan, G; Pandey, SK; Sergeev, E; Ulven, T | 1 |
| Beetens, J; Galien, R; Namour, F; Van der Aa, A; Van Kaem, T; Van't Klooster, G; Vanhoutte, F | 1 |
| Itoh, H; Kanayama, N; Matsuya-Ogawa, M; Murakami, H; Shibata, T; Sugihara, K; Yaguchi, C | 1 |
| Gates, EJ; Klegeris, A; Ranger, AL; Wenzel, TJ | 1 |
| Bartoszek, A; Binienda, A; Dziedziczak, K; Fabisiak, A; Fichna, J; Kordek, R; Krajewska, JB; Makaro, A; Mosińska, P; Niewinna, K; Salaga, M; Świerczyński, M; Talar, M; Tarasiuk, A | 1 |
1 trial(s) available for thiophenes and 4-(((r)-1-(benzo(b)thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl)-(3-chloro-benzyl)-amino)-butyric acid
| Article | Year |
|---|---|
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects.
Topics: Adolescent; Adult; Butyrates; Cell Movement; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Neutrophil Activation; Receptors, Cell Surface; Thiophenes; Young Adult | 2016 |
5 other study(ies) available for thiophenes and 4-(((r)-1-(benzo(b)thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl)-(3-chloro-benzyl)-amino)-butyric acid
| Article | Year |
|---|---|
Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azetidines; Butyrates; Humans; Immune System Diseases; Inhibitory Concentration 50; Leukocyte Disorders; Mice; Microsomes, Liver; Rats, Sprague-Dawley; Receptors, Cell Surface; Structure-Activity Relationship; Thiophenes | 2014 |
Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands.
Topics: Amino Acids; Binding Sites; Binding, Competitive; Butyrates; Butyric Acid; Esters; HEK293 Cells; Humans; Kinetics; Ligands; Models, Molecular; Mutant Proteins; Receptors, Cell Surface; Thiophenes; Tritium | 2016 |
Oncoprotective Effects of Short-Chain Fatty Acids on Uterine Cervical Neoplasia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Butyrates; Cell Proliferation; Fatty Acids, Volatile; Female; HeLa Cells; Humans; Immunohistochemistry; Middle Aged; Neoplasm Grading; Receptors, Cell Surface; Thiophenes; Uterine Cervical Neoplasms | 2019 |
Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells.
Topics: Butyrates; Chemokine CCL2; Fatty Acids, Volatile; Humans; Inflammation; Microglia; Monocytes; Thiophenes; Tumor Necrosis Factor-alpha | 2020 |
Characterization of the Synergistic Effect between Ligands of Opioid and Free Fatty Acid Receptors in the Mouse Model of Colitis.
Topics: Aniline Compounds; Animals; Butyrates; Colitis; Disease Models, Animal; Drug Synergism; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Inflammation; Ligands; Male; Mice; Mice, Inbred BALB C; Naloxone; Narcotic Antagonists; Peroxidase; Receptors, G-Protein-Coupled; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu; Sulfonamides; Thiophenes; Xanthenes | 2021 |